Purpose of Review
Despite the high prevalence and impact of osteoporosis, screening and treatment rates remain low, with few women age 65 years and older utilizing osteoporosis screening for primary prevention.
This review examines opportunities and challenges related to primary prevention and screening for osteoporosis at the population level. Strategies on how to identify individuals at high fracture risk and target them for treatment have lagged far behind other developments in the osteoporosis field. Most osteoporosis quality improvement strategies have focused on patients with recent or prior fracture (secondary prevention), with limited attention to individuals without prior fracture. For populations without prior fracture, the only quality improvement strategy for which meta-analysis demonstrated significant improvement in osteoporosis care was patient self-scheduling of DXA plus education
Much more work is needed to develop and validate effective primary screening and prevention strategies and translate these into high-quality guidelines.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364–76. https://doi.org/10.1016/s0140-6736(18)32112-3.
Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20(7):1185–94. https://doi.org/10.1359/JBMR.050304.
Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18(8):1033–46. https://doi.org/10.1007/s00198-007-0343-y.
Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2012;97(6):1871–80. https://doi.org/10.1210/jc.2011-3060.
Saito T, Sterbenz JM, Malay S, Zhong L, MacEachern MP, Chung KC. Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. Osteoporos Int. 2017;28(12):3289–300. https://doi.org/10.1007/s00198-017-4175-0.
Laliberte MC, Perreault S, Jouini G, Shea BJ, Lalonde L. Effectiveness of interventions to improve the detection and treatment of osteoporosis in primary care settings: a systematic review and meta-analysis. Osteoporos Int. 2011;22(11):2743–68. https://doi.org/10.1007/s00198-011-1557-6.
Khosla S, Cauley JA, Compston J, Kiel DP, Rosen C, Saag KG, et al. Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res. 2016. https://doi.org/10.1002/jbmr.3074.
Little EA, Eccles MP. A systematic review of the effectiveness of interventions to improve post-fracture investigation and management of patients at risk of osteoporosis. Implement Sci. 2010;5:80. https://doi.org/10.1186/1748-5908-5-80.
Mitchell PJ. Best practices in secondary fracture prevention: fracture liaison services. Curr Osteoporos Rep. 2013;11(1):52–60. https://doi.org/10.1007/s11914-012-0130-3.
Osuna PM, Ruppe MD, Tabatabai LS. Fracture liaison services: multidisciplinary approaches to secondary fracture prevention. Endocr Pract. 2017;23(2):199–206. https://doi.org/10.4158/EP161433.RA.
Warriner AH, Outman RC, Feldstein AC, Roblin DW, Allison JJ, Curtis JR, et al. Effect of self-referral on bone mineral density testing and osteoporosis treatment. Med Care. 2014;52(8):743–50. https://doi.org/10.1097/MLR.0000000000000170.
• Gillespie CW, Morin PE. Trends and disparities in osteoporosis screening among women in the United States, 2008-2014. Am J Med. 2017;130(3):306–16. https://doi.org/10.1016/j.amjmed.2016.10.018. De-identified administrative claims information for over 100 million Medicare Advantage and commercial enrollees, 2008–1014. Study participants included 1,638,454 women ages 50+ with no prior history of osteoporosis diagnosis, osteoporosis drug use, or hip fracture. Osteoporosis screening rates during the 2-year period were low: 21.1%, 26.5%, and 12.8% among women ages 50–64, 65–79, and 80+ years, respectively. Between 2008 and 2014, utilization among women ages 50–64 years declined 31.4%, changed little among women 65–79, and increased 37.7% among women 80+ years.
Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporos Int. 2017;28(2):643–52. https://doi.org/10.1007/s00198-016-3782-5.
Su Y, Lai FTT, Yip BHK, Leung JCS, Kwok TCY. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong. Osteoporos Int. 2018. https://doi.org/10.1007/s00198-018-4543-4.
•• Gourlay ML, Overman RA, Fine JP, Crandall CJ, Robbins J, Schousboe JT, et al. Time to clinically relevant fracture risk scores in postmenopausal women. Am J Med. 2017;130(7):862 e15–23. https://doi.org/10.1016/j.amjmed.2017.02.012. Postmenopausal women aged 50–64 years who had low FRAX-predicted fracture risk (major osteoporotic fracture risk < 9.2%) at baseline were highly unlikely to develop a treatment-level FRAX score even after 16 years of follow-up.
•• Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R, Fordham R, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018;391(10122):741–7. https://doi.org/10.1016/S0140-6736(17)32640-5. Compared with routine care, community-based osteoporosis screening in the UK using age-specific FRAX thresholds did not reduce osteoporosis-related fractures overall but reduced the secondary endpoint of hip fractures by 28%.
• Turner DA, Khioe RFS, Shepstone L, Lenaghan E, Cooper C, Gittoes N, et al. The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: economic evaluation of the SCOOP Study. J Bone Miner Res. 2018. https://doi.org/10.1002/jbmr.3381. In the SCOOP trial of community-based osteoporosis screening versus routine care in the women aged 70–85 years in the UK, the FRAX-based screening strategy was highly cost-effective.
• McCloskey E, Johansson H, Harvey NC, Shepstone L, Lenaghan E, Fordham R, et al. Management of patients with high baseline hip fracture risk by FRAX reduces hip fractures-a post hoc analysis of the SCOOP study. J Bone Miner Res. 2018. https://doi.org/10.1002/jbmr.3411. In the SCOOP randomized trial of FRAX-based osteoporosis screening versus usual care in older women, the efficacy of the screening intervention in reducing hip fracture risk was not observed in women with the lowest baseline FRAX-predicted hip fracture risk.
•• Rubin KH, Rothmann MJ, Holmberg T, Hoiberg M, Moller S, Barkmann R, et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int. 2017. https://doi.org/10.1007/s00198-017-4326-3. The ROSE trial tested a community-based osteoporosis screening intervention versus usual care among women aged 65–80 years in Denmark. Compared with usual care, the FRAX-based screening intervention did not decrease osteoporosis-related fractures, but decreased the secondary outcomes of hip fractures and major osteoporotic fractures.
• Rothmann MJ, Moller S, Holmberg T, Hojberg M, Gram J, Bech M, et al. Non-participation in systematic screening for osteoporosis-the ROSE trial. Osteoporos Int. 2017. https://doi.org/10.1007/s00198-017-4205-y. In the ROSE trial of FRAX-based screening vs. usual care in older women, certain factors were associated with lower likelihood of accepting DXA screening, including higher alcohol consumption, older age, current smoking, and physical impairment.
•• Crandall CJ, Larson J, Manson JE, Cauley JA, LaCroix AZ, Wactawski-Wende J, et al. A comparison of US and Canadian osteoporosis screening and treatment strategies in postmenopausal women. J Bone Miner Res. 2019;34(4):607–15. https://doi.org/10.1002/jbmr.3636. Among postmenopausal women 50–64 years old in the Women’s Health Initiative Study, both the US Preventive Services Task Force and the Canadian osteoporosis screening strategies failed to identify the majority of women who actually experienced major osteoporotic fractures during 10 years of follow-up. Better screening algorithms are needed for women aged 50–64 years.
•• Crandall CJ, Schousboe JT, Morin SN, Lix LM, Leslie W. Performance of FRAX and FRAX-based treatment thresholds in women aged 40 years and older: the Manitoba BMD registry. J Bone Miner Res. 2019;34(8):1419–27. https://doi.org/10.1002/jbmr.3717. For identifying women aged age 40 who experience major osteoporotic fractures during 10 years of follow-up, femoral neck bone mineral density T-score and FRAX-predicted fracture risk used as a continuous measures each predicted fracture risk well. However, thresholds of bone density or FRAX score recommended by treatment guidelines had low sensitivity for identifying women who experienced incident major osteoporotic fractures, suggesting that threshold-based approaches should be reassessed particularly in younger postmenopausal women.
Gourlay ML, Ritter VS, Fine JP, Overman RA, Schousboe JT, Cawthon PM, et al. Comparison of fracture risk assessment tools in older men without prior hip or spine fracture: the MrOS study. Arch Osteoporos. 2017;12(1):91. https://doi.org/10.1007/s11657-017-0389-1.
• Diem SJ, Peters KW, Gourlay ML, Schousboe JT, Taylor BC, Orwoll ES, et al. Screening for osteoporosis in older men: operating characteristics of proposed strategies for selecting men for BMD testing. J Gen Intern Med. 2017. https://doi.org/10.1007/s11606-017-4153-4. In untreated older men, the Osteoporosis Self-Assessment Tool performed as well as the FRAX tool in identifying osteoporosis while FRAX performed better for identifying men qualifying for NOF guidelines-based treatment. Both strategies reduced the proportion of men referred for BMD testing compared with universal screening.
Crandall CJ, Larson J, LaCroix A, Cauley JA, LeBoff MS, Li W, et al. Predicting fracture risk in younger postmenopausal women: comparison of the Garvan and FRAX risk calculators in the women’s health initiative study. J Gen Intern Med. 2018. https://doi.org/10.1007/s11606-018-4696-z.
Colon-Emeric CS, Pieper CF, Van Houtven CH, Grubber JM, Lyles KW, Lafleur J, et al. Limited osteoporosis screening effectiveness due to low treatment rates in a national sample of older men. Mayo Clin Proc. 2018;93(12):1749–59. https://doi.org/10.1016/j.mayocp.2018.06.024.
• Leslie WD, Seeman E, Morin SN, Lix LM, Majumdar SR. The diagnostic threshold for osteoporosis impedes fracture prevention in women at high risk for fracture: a registry-based cohort study. Bone. 2018;114:298–303. https://doi.org/10.1016/j.bone.2018.07.004. "Guidelines are not enough." Among 3735 screened untreated women qualifying for treatment, only half actually initiated treatment. Presence/absence of a BMD T-score in the osteoporotic range was the primary determinant of treatment, even for those with prior vertebral fracture, hip fracture, or multiple fractures.
Lorentzon M, Nilsson AG, Johansson H, Kanis JA, Mellstrom D, Sundh D. Extensive undertreatment of osteoporosis in older Swedish women. Osteoporos Int. 2019;30(6):1297–305. https://doi.org/10.1007/s00198-019-04872-4.
Wu CH, Kao IJ, Hung WC, Lin SC, Liu HC, Hsieh MH, et al. Economic impact and cost-effectiveness of fracture liaison services: a systematic review of the literature. Osteoporos Int. 2018;29(6):1227–42. https://doi.org/10.1007/s00198-018-4411-2.
Wu CH, Tu ST, Chang YF, Chan DC, Chien JT, Lin CH, et al. Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. Bone. 2018;111:92–100. https://doi.org/10.1016/j.bone.2018.03.018.
Gehlbach SH, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood JR. Recognition of vertebral fracture in a clinical setting. Osteoporos Int. 2000;11(7):577–82. https://doi.org/10.1007/s001980070078.
Barton DW, Behrend CJ, Carmouche JJ. Rates of osteoporosis screening and treatment following vertebral fracture. Spine J. 2018. https://doi.org/10.1016/j.spinee.2018.08.004.
Pickhardt PJ, Pooler BD, Lauder T, del Rio AM, Bruce RJ, Binkley N. Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications. Ann Intern Med. 2013;158(8):588–95. https://doi.org/10.7326/0003-4819-158-8-201304160-00003.
Lee SJ, Pickhardt PJ. Opportunistic screening for osteoporosis using body CT scans obtained for other indications: the UW experience. Clin Rev Bone Miner Metab. 2017;15(3):128–37. https://doi.org/10.1007/s12018-017-9235-7.
Pickhardt PJ, Lee SJ, Liu J, Yao J, Lay N, Graffy PM, et al. Population-based opportunistic osteoporosis screening: validation of a fully automated CT tool for assessing longitudinal BMD changes. Br J Radiol. 2019;92(1094):20180726. https://doi.org/10.1259/bjr.20180726.
Li YL, Wong KH, Law MW, Fang BX, Lau VW, Vardhanabuti VV, et al. Opportunistic screening for osteoporosis in abdominal computed tomography for Chinese population. Arch Osteoporos. 2018;13(1):76. https://doi.org/10.1007/s11657-018-0492-y.
Buckens CF, Dijkhuis G, de Keizer B, Verhaar HJ, de Jong PA. Opportunistic screening for osteoporosis on routine computed tomography? An external validation study. Eur Radiol. 2015;25(7):2074–9. https://doi.org/10.1007/s00330-014-3584-0.
Bar A, Wolf L, Amitai OB, Toledano E, Elnekave E, editors. Compression fractures detection on CT. Medical Imaging 2017: computer-aided diagnosis; 2017: International Society for Optics and Photonics.
Williams ST, Lawrence PT, Miller KL, Crook JL, LaFleur J, Cannon GW, et al. A comparison of electronic and manual fracture risk assessment tools in screening elderly male US veterans at risk for osteoporosis. Osteoporos Int. 2017. https://doi.org/10.1007/s00198-017-4172-3.
Goldshtein I, Ish-Shalom S, Leshno M. Impact of FRAX-based osteoporosis intervention using real world data. Bone. 2017;103:318–24. https://doi.org/10.1016/j.bone.2017.07.027.
Goldshtein I, Gerber Y, Ish-Shalom S, Leshno M. Fracture Risk Assessment with FRAX using real-world data: a population-based cohort from Israel. Am J Epidemiol. 2017. https://doi.org/10.1093/aje/kwx128.
Reber KC, Konig HH, Becker C, Rapp K, Buchele G, Machler S, et al. Development of a risk assessment tool for osteoporotic fracture prevention: a claims data approach. Bone. 2018;110:170–6. https://doi.org/10.1016/j.bone.2018.02.002.
Yang S, Leslie WD, Morin SN, Lix LM. Administrative healthcare data applied to fracture risk assessment. Osteoporos Int. 2019;30(3):565–71. https://doi.org/10.1007/s00198-018-4780-6.
•• Rubin KH, Moller S, Holmberg T, Bliddal M, Sondergaard J, Abrahamsen B. A new fracture risk assessment tool (FREM) based on public health registries. J Bone Miner Res. 2018. https://doi.org/10.1002/jbmr.3528. Ambitious derivation and internal validation of FREM—Fracture Risk Evaluation Model—for automated case finding of high-risk individuals of hip or major osteoporotic fractures (MOF) using the population in Denmark aged 45+ years (N = 2,495,339), all hospital diagnoses from 1998 to 2012 and fracture outcomes during 2013. FREM for MOF (38 and 43 risk factors for women and men, respectively) in the validation cohort showed high accuracy (AUC 0.750, 95% CI 0.741, 0.795, and 0.752, 95% CI 0.743, 0.761 for women and men, respectively). FREM for hip fractures included 32 risk factors for both genders and gave AUC 0.874 (95% CI 0.869, 0.879) and 0.851 (95% CI 0.841, 0.861) for women and men.
Negm AM, Ioannidis G, Jantzi M, Bucek J, Giangregorio L, Pickard L, et al. Validation of a one year fracture prediction tool for absolute hip fracture risk in long term care residents. BMC Geriatr. 2018;18(1):320. https://doi.org/10.1186/s12877-018-1010-1.
Berry SD, Zullo AR, Lee Y, Mor V, McConeghy KW, Banerjee G, et al. Fracture risk assessment in long-term care (FRAiL): development and validation of a prediction model. J Gerontol A Biol Sci Med Sci. 2018;73(6):763–9. https://doi.org/10.1093/gerona/glx147.
Hayawi LM, Graham ID, Tugwell P, Yousef AS. Screening for osteoporosis: a systematic assessment of the quality and content of clinical practice guidelines, using the AGREE II instrument and the IOM Standards for Trustworthy Guidelines. PLoS One. 2018;13(12):e0208251. https://doi.org/10.1371/journal.pone.0208251.
• Molino C, Leite-Santos NC, Gabriel FC, Wainberg SK, Vasconcelos LP, Mantovani-Silva RA, et al. Factors associated with high-quality guidelines for the pharmacologic management of chronic diseases in primary care: a systematic review. JAMA Intern Med. 2019. https://doi.org/10.1001/jamainternmed.2018.7529. This monumental study addresses the question "What makes a high-quality clinical practice guideline in primary care?" based upon the validated Appraisal of Guidelines for Research and Evaluation Instrument, version II (AGREE-II) instrument. The most important factors: having more than 20 authors (odds ratio, 9.08; 95% CI 3.35–24.62), development at governmental institutions (odds ratio, 10.38; 95% CI 2.72–39.60), and reporting funding (odds ratio, 10.34; 95% CI 4.77–22.39).
• Nayak S, Greenspan SL. How can we improve osteoporosis care? A systematic review and meta-analysis of the efficacy of quality improvement strategies for osteoporosis. J Bone Miner Res. 2018;33(9):1585–94. https://doi.org/10.1002/jbmr.3437. A comprehensive review of what works and what does not to improve osteoporosis screening and/or treatment rates. Secondary prevention strategies seem to be better developed and more successful than primary prevention srategieis.
Conflict of Interest
William D. Leslie and Carolyn J. Crandall declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Quality of Care in Osteoporosis
About this article
Cite this article
Leslie, W.D., Crandall, C.J. Population-Based Osteoporosis Primary Prevention and Screening for Quality of Care in Osteoporosis, Current Osteoporosis Reports. Curr Osteoporos Rep 17, 483–490 (2019). https://doi.org/10.1007/s11914-019-00542-w
- Primary prevention
- Dual-energy X-ray absorptiometry